Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Basic Physician's Training Monash > IBs, MABs, and fancy things > Flashcards

IBs, MABs, and fancy things Flashcards

1
Q

Adalimumab: Target and disease

A

Anti-TNF

RA, Psoriatic, arthritis, Ank spond

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Afatinib: Target and disease

A

EGFR inhibitor

NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Alemtuzumab: Target and disease

A

Anti-CD52
MS, CML, cutaneous T cell lymphoma, transplant induction

AE: CMV, Hypersensitivity, profound lymphopenia >12mo, Autoimmune diseases (ITP, thyroid)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Anakinra: Target and disease

A

IL1 blockade
Autoinflammatory blockade
Typically in still’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Axitinib: Target and disease

A

VEGF mainly, PDGFRB, c-KIT

2nd line RCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Basiliximab: Target and disease

A

Anti-IL2R – Anti-CD25

Renal transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Belatacept: Target and disease

A

CTLA4 fused with Fc, blocks T cell co-stimulation

Renal transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Belimumab: Target and disease

A

Anti-BLys/BAFF

SLE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Benralizumab: Target and disease

A

Anti-IL5 receptor alpha

Asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bevacizumab: Target and disease

A

Anti-VEGF
Colorectal, ovarian, CNS, cancer, proliferative diabetic retinopathy (intravitreal inj)
AE: HTN, GN, poor wound healing, thrombosis, nasal septal perforation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bezlotoxumab: Target and disease

A

Anti-C.Difficile toxin B

Preventing C. Diff recurrence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Blinatumomab: Target and disease

A

Bi-specific T-cell engaging antibody
Engages CD3 on T-cell to CD19 on B cell
ALL relapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Bortezomib (Valcade): Target and disease

A

Inhibit NF-kappaB
Multiple myeloma
AE Neuropathy, thrombocytopaenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Brentuximab: Target and disease

A

Anti-CD30

Hodgkin’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Brodalumab: Target and disease

A

Anti-IL17R

Psoriasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Canakinumab: Target and disease

A

Anti-IL1b

RA, Autoinflammatory disease, gout

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Certolizumab: Target and disease

A

Anti-TNF
Crohn’s, RA, psoriatic, Ank spond, Crohn’s
Does not cross placenta

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Cetuximab: Target and disease

A

EGFR inhibitor
Met CRC (KRAS wild type), head and neck SCC
AE: Acneiform rash, diarrhoea, ILD, conjuctivitis, electrolytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Crizanlizumab: Target and disease

A

PSGL1

Sickle-cell crisis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Crizotinib: Target and disease

A

ALK and ROS-1
NSCLC
Poor cns penetrance
AE: visual phenomenon, bradycardia, hepatitis, pneumonitis, N+V+D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Dabrafenib: Target and disease

A

BRAF inhibitor

BRAF positive melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Dasatinib: Target and disease

A

BCR-ABL
2nd line in CML
AE: PLT dysfunction, pleural effusion, prolonged QT, diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Denosumab: Target and disease

A

RANK-L inhibitor
Osteoporosis
Prevents osteoclast maturation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Eculizumab: Target and disease

A

Anti-C5
PNH, aHUS
AE; Meningitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Eltrombopag: Target and disease
TPO receptor agonist | ITP
26
Erlotinib: Target and disease
EGFR inhibitor NSCLC AE: acne, diarrhea, pneumonitis, hepatitis
27
Evolocumab: Target and disease
PCSK9 inhibitor Increases hepatic cholesterol uptake Hypercholesterolaemia
28
Etanercept: Target and disease
TNF blockade | RA, Psoriatic, ank spond
29
Gefitinib: Target and disease
EGFR inhibitor | NSCLC
30
Golimumab: Target and disease
Anti-TNF | RA, psoriatic, ank spond, UC
31
Ibritumomab: Target and disease
Anti-CD20 bound to radioisotope | Non-hodgkin's
32
Ocrelizumab: Target and disease
Anti-CD20 | MS
33
Ibrutinib: Target and disease
``` BTK inhibitor (B-cell) CLL, Waldenstrom's, mantle cell, marginal zone, Chronic GVHD AE: AF, diarrhoea, platelet dysfunction, fluid retention ```
34
Idelalisib: Target and disease
P13K inhibitor 2nd line CLL Non hodgkins lymphoma
35
Idarucizumab: Target and disease
Dabigatran reversal
36
Imatinib: Target and disease
BCR-ABL and cKIT mutations CML, GIST, ALL Hypereosinophilia with FGFR1/PDGFR alpha mutation AE: muscle cramps, maculopapular rash, fatigue, pleural effusions/oedema
37
Infliximab: Target and disease
Anti-TNF Crohn's, other stuff AE: Serious infection, TB activation, increased risk of skin caner, demyelinating disease flare
38
Ipilimumab: Target and disease
Anti-CTLA4 Metastatic melanoma Auto-immune AE, more than PD1
39
Ixekizumab: Target and disease
Anti-IL17a | Psoriasis, spondyloarthropathies
40
Lapatinib: Target and disease
HER2 Her2+ breast Ca AE; Hand foot syndrome
41
Mepolizumab: Target and disease
Anti-IL5 | Eosinophilic asthma
42
Natalizumab: Target and disease
Anti-a4 integrin MS AE; PML Brain homing T cells express alpha 4 beta 1
43
Nilotinib: Target and disease
BCR-ABL inhibitor 2nd line CML off-label GIST AE: long QT, pancreatitis long term cardiovascular, PAH, inhibition of platelet function
44
Nintedanib: Target and disease
VEGFR, FGFR IPF AE; Diarrhoea, deranged LFT
45
Nivolumab: Target and disease
Anti-PD1 Melanoma, NSCLC Pneumonitis/thyroiditis more than CTLA4
46
Obinutuzumab: Target and disease
Anti-CD20 CLL Follicular lymphoma
47
Ofatumumab: Target and disease
Anti-CD20 | Refractory CLL
48
Omalizumab: Target and disease
Anti-IgE | Asthma
49
Olaparib: Target and disease
PARP inhibitor BRCA mutant high grade serous ovarian, fallopian tube, primary peritoneal, breast cancer SE: myelosuppression, nausea, fatigue
50
Osimertinib: Target and disease
EGFR inhibitor - T790M | 2nd line NSCLC if T790M +ve
51
Palbociclib: Target and disease
CDK4/6 inhibitor Metastatic ER+ breast cancer AE: neutropaenia
52
Panitumumab: Target and disease
Anti-EGFR | CRC
53
Pazopanib: Target and disease
VEGF, PDGFR, KIT RCC Sarcoma
54
Pembrolizumab: Target and disease
Anti-PD1 | Melanoma, NSCLC (PDL1>50%)
55
Durvalumab: Target and disease
Anti-PDL1 | stage III NSCLC
56
Pertuzumab: Target and disease
Anti-HER2/HER3 Metastatic HER2+ breast cancer Minimal benefit in adjuvant
57
Ponatinib: Target and disease
BCR-ABL 3rd line CML - targets t315i mutation AE: rash, pancreatitis, vascular events
58
Ramucirumab: Target and disease
Anti-VEGF | Gastric cancer
59
Reslizumab: Target and disease
Anti-IL5 | Asthma
60
Rituximab: Target and disease
Anti-CD20 | Non-hodgkin's, many others
61
Romosozumab: Target and disease
Sclerostin inhibitor | Osteoporosis
62
Ruxolitinib: Target and disease
Jak1/2 inhibitor | Myelofibrosis, PRV (resistant to hydroxyurea)
63
Secukinumab: Target and disease
Anti-IL17 | Psoriasis
64
Siltuximab: Target and disease
Anti-IL6 | Castleman disease
65
Sorafenib: Target and disease
VEGFR2/3, PDGFR, C-raf>B-raf, KIT | RCC, HCC, Thyroid cancer
66
Sunitinib: Target and disease
FGF, PDGFR, RET< FLT3, VEGFR1/2, c-KIT GIST, RCC, Pancreatic NET AE: MAHA/HUS/TTP, myelosuppression, GI toxicity, hand/foot syndrome, hepatotoxicity, pancreatitis, cardiotoxicity
67
Tocilizumab: Target and disease
Anti-IL6 RA, GCA AE: Bowel perforation
68
Tofacitinib: Target and disease
JAK3 RA, UC AE: Shingles
69
Trametinib: Target and disease
MEK1/2 | Melanoma (BRAF positive
70
Trastuzumab: Target and disease
HER2 | HER2+ breast Ca
71
TDM-1: Target and disease
Also known as Trastuzumab/emtansine HER2 mab with chemo 2nd line HER2+ breast Ca
72
Ustekinumab: Target and disease
Anti IL12/23 (p40 subunit) Crohn's, psoriasis Spondyloarthropathies (not for axial disease)
73
Vedolizumab: Target and disease
Anti-a4b7 integrin UC, Crohn's (better in UC) Gut homing T cells express a4b7
74
Vemurafenib: Target and disease
BRAF inhibitor BRAF pos melanoma AE: Photosensitivity, arthralgia
75
Andaxanet alfa: Target and disease
Reversal of apixaban, rivaroxaban
76
Ceritinib: Target and disease
2nd line ALK inhibitor | Nsclc
77
Alectinib: Target and disease
2nd line ALK inhibitor | Nsclc
78
Romiplostim: Target and disease
TPO receptor antagonist | ITP not suitable for splenectomy or post splenectomy
79
Emicizumab: Target and indication
Mimics factor VIII (Biallelic antibody to factor IX and X) | Severe Haemophilia A
80
Venetoclax: Target and disease
BCL2 | CLL, MPN1 positive AML
81
Regorafenib: Target and disease
VEGF, KIT, TIE2, PDGFR | CRC (2nd/3rd line), GIST (2nd line)
82
Ribociclib: Target and disease
CDK4/6 inhibitor Metastatic ER+ breast cancer AE: neutropaenia
83
Fingolimod: Target and disease
Downregulates sphingosine-1-phosphate receptors, Decreases ability of lymphocytes to enter CNS AE: bradycardia/heart block, macular oedema
84
Erenumab: Target and disease
Recombinant human monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP) vasodilation by blocking CGRP receptors Migraine Prophylaxis
85
Icatibant: Target and indication
Bradykinin receptor antagonist | Hereditary angioedema treatment of attacks
86
Rilonacept: Target and indication
IL-1 Trap Dimeric fusion protein incorporating components of IL-1R Severe RA Autoinflammatory diseases
87
Abatacept: Target and indication
CTLA-4 bound to Fc end of Ig=B7 blocker Prevents T cell activation RA
88
Dupilumab: Target and indication
Anti IL-4 receptor alpha Atopic dermatitis
89
Daratumumab: Target and indication
Anti-CD38 Myeloma Interference with indirect anti globulin tests. Need to send extended red blood cell phenotype and RBC antibody screen before 1st dose

Basic Physician's Training Monash (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions